Fujian Wanchen Biotechnology Co., Ltd engages in the research and development, cultivation, production, and sale of edible fungi in China. It offers flammulina velutipes; and crab-flavored, white jade, seafood mushrooms, etc. The company was founded in 2011 and is based in Zhangpu, China.
Fujian Wanchen Biotechnology Co. Ltd (300972) - Total Liabilities
Latest total liabilities as of March 2025: CN¥4.93 Billion CNY
Based on the latest financial reports, Fujian Wanchen Biotechnology Co. Ltd (300972) has total liabilities worth CN¥4.93 Billion CNY as of March 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Fujian Wanchen Biotechnology Co. Ltd - Total Liabilities Trend (2019–2024)
This chart illustrates how Fujian Wanchen Biotechnology Co. Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Fujian Wanchen Biotechnology Co. Ltd Competitors by Total Liabilities
The table below lists competitors of Fujian Wanchen Biotechnology Co. Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Jiangsu Expressway Company Limited
PINK:JEXYF
|
USA | $40.52 Billion |
|
Foot Locker Inc
NYSE:FL
|
USA | $3.95 Billion |
|
Mapletree Commercial Trust
PINK:MPCMF
|
USA | $6.52 Billion |
|
TMBThanachart Bank Public Company Limited
F:NVPJ
|
Germany | €1.51 Trillion |
|
Stock Yards Bancorp Inc
NASDAQ:SYBT
|
USA | $8.02 Billion |
|
Suzhou Novosense Microelectronics Co. Ltd.
SHG:688052
|
China | CN¥1.73 Billion |
|
Taiwan High Speed Rail Corp
TW:2633
|
Taiwan | NT$311.80 Billion |
Liability Composition Analysis (2019–2024)
This chart breaks down Fujian Wanchen Biotechnology Co. Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.28 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 3.73 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.73 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Fujian Wanchen Biotechnology Co. Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Fujian Wanchen Biotechnology Co. Ltd (2019–2024)
The table below shows the annual total liabilities of Fujian Wanchen Biotechnology Co. Ltd from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥5.79 Billion | +79.35% |
| 2023-12-31 | CN¥3.23 Billion | +510.75% |
| 2022-12-31 | CN¥528.79 Million | +151.24% |
| 2021-12-31 | CN¥210.47 Million | -18.40% |
| 2020-12-31 | CN¥257.94 Million | -17.01% |
| 2019-12-31 | CN¥310.81 Million | -- |